


HealthLinx



6¢	52wk high	14.5¢	Fwd EPS	n/a
1x	52wk low	7¢	Fwd P/E	n/a
1%	1yr return	5.26%	Div yield	n/a

by Cancer test on track

Junior biotechnology company HealthLinx believes it is on track to develop one of the first ovarian cancer diagnostics on the market by the second quarter of 2008. The company recently signed a deal with the University of Liverpool to licence a number of technologies and antibodies to help its development of the cancer test. Phase II test results for its ovarian cancer screen show a 15 per cent improvement in diagnostic efficiency. HealthLinx's patented technology has recorded success in detecting ovarian cancer at an early stage in the deadly disease. It is a non-invasive, serum-based technology. The company will also begin trialling a second-generation ovarian cancer diagnostic this year. The second-generation test will be able to detect the tumour type and pick up signs of ovarian cancer at an early stage.